HighTower Advisors’s Atara Biotherapeutics ATRA Stock Holding History

HighTower Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-424	Closed	-$42K	–	3352
2022 Q3	$42K	Buy	+424	New	+$47.6K	﹤0.01%	2902
2021 Q1	–	Sell	-534	Closed	-$264K	–	3049
2020 Q4	$264K	Buy	+534	New	+$246K	﹤0.01%	2016
2020 Q2	–	Sell	-535	Closed	-$115K	–	2434
2020 Q1	$115K	Buy	+535	New	+$170K	﹤0.01%	1918
2019 Q4	–	Sell	-867	Closed	-$301K	–	2343
2019 Q3	$301K	Buy	867 +99	+13%	+$36.9K	﹤0.01%	1786
2019 Q2	$383K	Hold	768	–	–	﹤0.01%	1653
2019 Q1	$768K	Sell	768 -20	-3%	-$18.6K	0.01%	1257
2018 Q4	$682K	Buy	788 +24	+3%	+$22.3K	0.01%	1206
2018 Q3	$784K	Buy	764 +2	+0.3%	+$1.96K	0.01%	1240
2018 Q2	$697K	Sell	762 -78	-9%	-$83.8K	0.01%	1298
2018 Q1	$820K	Buy	+840	New	+$765K	0.01%	1178

Other funds holding ATRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

HighTower Advisors's ATRA Position: Q4 2022 in Review

HighTower Advisors sold out of Atara Biotherapeutics (ATRA) in Q4 2022, closing a stake of 424 shares — an estimated $42K sold.

HighTower Advisors first reported a position in ATRA in Q1 2018 and held it in 10 quarters. The position peaked at $820K in Q1 2018. 138 funds tracked by Wall St. Rank hold ATRA as of Q4 2022.

HighTower Advisors reported no remaining Atara Biotherapeutics position as of Q4 2022 after selling out during the quarter.
HighTower Advisors sold 424 Atara Biotherapeutics shares in Q4 2022, an estimated $42K.
HighTower Advisors first reported a position in Atara Biotherapeutics in Q1 2018 and held it in 10 quarters.
HighTower Advisors's Atara Biotherapeutics position peaked at $820K in Q1 2018.
138 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2022.

Based on HighTower Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.